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Original Article
Effect of Flibanserin Treatment on Body Weight
in Premenopausal and Postmenopausal
Women with Hypoactive Sexual Desire Disorder:
A Post Hoc Analysis
Susan G. Kornstein, MD,1 James A. Simon, MD,2 Stuart C. Apfel, MD,3
James Yuan, MD, PhD, MBA,4 Krista A. Barbour, PhD, MPH,4 and Robert Kissling, MD4
Abstract
Background: Flibanserin, a 5-HT1A agonist and 5-HT2A antagonist, is indicated for the treatment of acquired,
generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This post hoc analysis evaluated
the effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with HSDD.
Materials and Methods: This analysis included three 24-week, double-blind, placebo-controlled studies of
flibanserin 100mg each bedtime (qhs) in premenopausal women, a similarly designed study in postmenopausal
women, and a 52-week, open-label extension study in premenopausal women.
Results: In a pooled analysis of premenopausal women, mean baseline body mass index (BMI) was 27.0 kg/m2 in
the flibanserin group (n= 1227) and 26.8 kg/m2 in the placebo group (n= 1238). Among patients who completed
24 weeks of treatment, least squares (LS) mean weight change was -1.4 kg in the flibanserin group (n= 1010) and
-0.1 kg in the placebo group (n= 1066; p< 0.0001). Weight loss ‡5% from baseline was reported in 21.0% of
patients who received flibanserin and 7.8% of patients who received placebo; weight loss ‡10% was reported in
3.8% and 2.0% of patients, respectively. In postmenopausal women, mean baseline BMI was 27.7 kg/m2 in the
flibanserin group (n= 467) and 27.3 kg/m2 in the placebo group (n= 480). LS mean weight change at week 24
was -1.8 kg in the flibanserin group (n= 385) and -0.1 kg in the placebo group (n= 425; p< 0.0001), with weight
loss ‡5% reported in 24.7% and 7.3% of patients, respectively, and weight loss ‡10% reported in 5.2% and 1.7%,
respectively. In HSDD patients with >12 months (n= 880) and >18 months (n= 637) of exposure to flibanserin,
mean weight change was -1.0 and -1.2 kg, respectively; 25.4% and 26.9% of patients, respectively, experienced
weight loss ‡5% from baseline, and 7.8% and 8.4%, respectively, experienced weight loss ‡10%.
Conclusions: Women treated with flibanserin for HSDD may experience weight loss.
Keywords: body weight, flibanserin, reproductive health, sexuality, weight loss
Introduction
Flibanserin is indicated for the treatment of acquired,generalized hypoactive sexual desire disorder (HSDD;
not limited to certain types of stimulation, situation, or
partner and developed after a period of normal sexual
functioning) in premenopausal women and is the only U.S.
Food and Drug Administration (FDA)-approved treatment
for HSDD.1,2 Flibanserin is a postsynaptic 5-HT1A agonist
and 5-HT2A antagonist that has been shown to induce de-
creases in serotonin and increases in dopamine and norepi-
nephrine in certain regions of the cerebral cortex.3–6
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By modulating these neurotransmitters, flibanserin is hy-
pothesized to restore balance to the activity of excitatory and
inhibitory influences on the regulation of a healthy sexual
response.7,8 The efficacy and safety of flibanserin in the
treatment of HSDD have been demonstrated in random-
ized clinical trials of premenopausal and postmenopausal
women9–13; however, flibanserin is not approved by the
FDA for use in postmenopausal women.
Serotonin neurons play a complex role in the regulation of
weight and metabolism, and pharmacologic agents with
serotonin-related activity have been shown to increase or
decrease body weight.14–19 Some serotonergic medications
(e.g., certain selective serotonin reuptake inhibitors [SSRIs])
are associated with weight gain.20,21 However, the selective
5-HT2C agonist lorcaserin is an FDA-approved weight-loss
treatment for patients who are obese (body mass index [BMI]
‡30 kg/m2) or overweight (BMI ‡27 kg/m2 in the presence of
‡1 weight-related comorbid condition, such as hypertension
or type 2 diabetes).22 The receptor binding profile of fli-
banserin suggests that it may have an impact on body weight
as well.
Data collected in the clinical development program for
flibanserin were utilized to retrospectively investigate the
effect of flibanserin treatment on body weight in women with
HSDD. Analyses included change in body weight associated
with flibanserin in premenopausal women (pooled data from
three randomized, placebo-controlled, 24-week trials9–11)
and postmenopausal women (in a randomized, placebo-
controlled, 24-week study13), and during long-term fli-
banserin use (in a 52-week, open-label, extension study23).
Materials and Methods
Study design and participants
This retrospective analysis included data from five
studies from the flibanserin clinical development program
in HSDD (Table 1).9–11,13,23 Study conduct was in com-
pliance with the principles of the Declaration of Helsinki
(1996) in accordance with the International Conference on
Harmonisation Good Clinical Practice guidelines. All study
protocols were approved by an institutional review board or
independent ethics committee, and all participants provided
written informed consent before the initiation of study
procedures.
Three patient populations were included in this analysis:
(1) premenopausal women ‡18 years old who were di-
agnosed with HSDD and enrolled in one of three
randomized, double-blind, placebo-controlled trials
that evaluated the safety and efficacy of flibanserin
(study names: VIOLET, DAISY, BEGONIA)9–11;
(2) naturally postmenopausal women of any age who were
diagnosed with HSDD and enrolled in a randomized,
double-blind, placebo-controlled trial evaluating the
safety and efficacy of flibanserin (SNOWDROP)13; and
(3) premenopausal women ‡18 years old who were di-
agnosed with HSDD and had participated in a ran-
domized placebo-controlled trial (VIOLET, DAISY,
DAHLIA),9,10 a randomized withdrawal study (ROSE),12
or a pharmacokinetic study of flibanserin and were
subsequently enrolled in a 52-week, open-label ex-
tension study (SUNFLOWER).23
Table 1. Studies Included in This Analysis
Study name Dates and locations Study design Participants Study medication







qhs (n = 295)a
NCT00360529 54 Sites in United States
and Canada
Flibanserin 100mg
qhs (n = 290)
Placebo (n = 295)







bid (n = 396)a
NCT00360555 77 Sites in United States
and Canada
Flibanserin 50mg
bid (n = 392)a
Flibanserin 100mg
qhs (n = 395)
Placebo (n = 398)









qhs (n = 542)
NCT00996164 75 Sites in United States Placebo (n = 545)








qhs (n = 467)











qhs or 25 or 50mg
bid flexibly dosed
(n= 1723 overall)
NCT00441558 201 Sites in United States
and Canada
aAnalyses of the placebo-controlled studies excluded patients who received flibanserin at doses other than 100mg qhs.
bid, twice daily; DB, double-blind; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision;
HSDD, hypoactive sexual desire disorder; OLE, open-label extension; PBO, placebo-controlled; qhs, each bedtime; R, randomized.
Data from Derogatis et al.,9 Thorp et al.,10 Katz et al.,11 Simon et al.,13 and Jayne et al.23 Additional information not found in these
sources is from original study data.























































The inclusion criteria for all studies in this analysis re-
quired that participants were diagnosed with generalized
acquired HSDD of ‡24 weeks’ duration (or ‡6 months’ du-
ration for the SNOWDROP study) according to the Diag-
nostic and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision (DSM-IV-TR) criteria.
Key exclusion criteria included other sexual dysfunctions;
major depressive disorder within the previous 6 months;
history of suicidal ideation or behavior; pelvic inflammatory
disease, urinary tract or vaginal infection/vaginitis, cervici-
tis, interstitial cystitis, vulvodynia, or significant vaginal at-
rophy; current pregnancy or pregnancy within the last month
(SUNFLOWER23 study) or last 6 months (VIOLET,9 DAISY,10
and BEGONIA studies); a history of cancer within the last 10
years; or blood abnormalities.
Use of certain medications was prohibited, including
sex hormones (except for hormonal contraceptives in pre-
menopausal women and systemic hormone therapy in post-
menopausal women), dopamine agonists, benzodiazepines,
prescription hypnotics, antidepressants, antipsychotics, mood
stabilizers, antiepileptics, St. John’s wort, metoclopramide, or
chronically used narcotics.11,13,23 None of the studies in this
analysis excluded patients on the basis of weight or BMI.
Patients received double-blind flibanserin or placebo in the
24-week randomized controlled trials and open-label flibanserin
in the 52-week extension study. To obtain information about
weight change associated with the recommended dose of fli-
banserin (100mg each bedtime [qhs]), analyses of the placebo-
controlled trials included only those patients treated with
flibanserin 100mg qhs or placebo. The long-term, open-label
study enrolled patients from a variety of flibanserin dosing
regimens (and some patients previously on placebo). All pa-
tients received flibanserin 50mg qhs for 4 weeks, with flexible
dosing thereafter to optimize efficacy and tolerability; permitted
doses were 50 or 100mg qhs, or 25 or 50mg twice per day.
None of the studies in this analysis was designed to eval-
uate weight loss as a clinical benefit of flibanserin treatment;
body weight was measured to assess weight loss and weight
gain as potential adverse effects.
Statistical analyses
The analysis population for the 24-week placebo-
controlled trials consisted of patients who were randomly
assigned to treatment, received at least one dose of study
medication, and had at least one assessment of body weight.
For the three 24-week studies of premenopausal women,
patient-level data were pooled by treatment group (fli-
banserin 100mg qhs vs. placebo) for assessments of body
weight at baseline, and weeks 8, 16, and 24.
In the premenopausal and postmenopausal patient popu-
lations, least-squares (LS) mean change in body weight from
baseline to week 24 was compared for flibanserin versus
placebo using analysis of covariance (ANCOVA) models
with treatment group as a factor and baseline bodyweight as a
covariate. In the premenopausal patient population, addi-
tional ANCOVA models were used to explore the effect of
potential confounding variables (i.e., use of SSRIs or sero-
tonin norepinephrine reuptake inhibitors [SNRIs], smoking
status, baseline BMI level [£25 or >25 kg/m2], hormonal
contraceptive use, and responder status on HSDD efficacy
measures) on weight change.
In each model, except that for BMI level, the variable of
interest and treatment group were used as factors with
baseline body weight as a covariate; because BMI and weight
are highly correlated, the model for BMI included baseline
BMI (rather than baseline weight) as the covariate.
The analysis population for ANCOVAs of HSDD re-
sponder status consisted of patients in the overall analysis
population who had at least one postbaseline efficacy assess-
ment. To identify patients with a clinically meaningful benefit
in HSDD symptoms, change from baseline to endpoint on
measures of sexual functioning (i.e., number of satisfying
sexual events [SSE], the Female Sexual Functioning Index-
desire domain [FSFI-D], and the Female Sexual Distress
Scale-Revised-desire item [FSDS-R13]) was anchored to re-
sponses on the Patient Global Impression of Improvement
(PGI-I) scale. For each measure of sexual functioning, a re-
sponder was defined as a patient with baseline to endpoint
score change greater than the corresponding minimal response
threshold (i.e., score of 3 [minimally improved]) on the PGI-I.
In the open-label extension study, change in body weight
was assessed for patients who had >12 months (365 days) and
>18 months (547 days) of exposure to flibanserin.
Results
Patients
Demographic and clinical characteristics of premeno-
pausal and postmenopausal women treated with flibanserin
100mg qhs or placebo in a 24-week randomized controlled
trial are shown in Table 2. In the pooled analysis of pre-
menopausal women, 1210 patients in the flibanserin group
and 1218 patients in the placebo group had at least 1 as-
sessment of body weight and were included in this analysis.
In the study of postmenopausal women, 467 flibanserin-
treated patients and 479 patients receiving placebo had at
least 1 assessment of body weight and were included in this
analysis. Within the premenopausal and postmenopausal
patient populations, characteristics were similar in the fli-
banserin and placebo groups. In the long-term, open-label
extension study, 880 patients received flibanserin for >12
months and 637 patients received flibanserin for >18 months.
Change in weight after 24 weeks of treatment
with flibanserin
At week 24, LSmean change (standard error) in weight was
-1.4 (0.1) kg in the flibanserin group and -0.1 (0.1) kg in the
placebo group in premenopausal women ( p< 0.0001) and -1.8
(0.2) kg in the flibanserin group and -0.1 (0.2) kg in the pla-
cebo group in postmenopausal women ( p< 0.0001) (Fig. 1).
Weight loss differed significantly by BMI in the premeno-
pausal patient population; greater LS mean weight loss was
observed in women with higher (>25kg/m2) versus lower
baseline BMI ( p< 0.01) (Table 3).
None of the other baseline factors investigated (i.e., SSRI/
SNRI use, smoking status, and hormonal contraceptive use)
had a significant effect on weight change, after account-
ing for the effects of baseline body weight and treatment
group. Similarly, there was no significant difference between
treatment responders and nonresponders (as determined
by change on HSDD efficacy measures [number of SSE,























































FIG. 1. Mean change from
baseline weight (kg) after 8, 16,
and 24 weeks of treatment with
flibanserin 100mg qhs or pla-
cebo in (A) premenopausal wo-
men and (B) postmenopausal
women. Mean (SD) baseline
weight was 73.7 (17.9) kg in the
flibanserin group and 73.1 (17.4)
kg in the placebo group for
premenopausal women, and
74.4 (15.4) kg in the flibanserin
group and 73.4 (15.2) kg in the
placebo group for postmeno-
pausal women. Error bars rep-
resent –1 standard error.
*p < 0.0001; {p < 0.005. qhs,
each bedtime; SD, standard
deviation.
Table 2. Demographic and Baseline Clinical Characteristics and Selected Concomitant
Medications in 24-Week Randomized Controlled Studies (All Treated Population)
Characteristics
Premenopausal womena Postmenopausal women
Flibanserin




100mg qhs (n = 467)
Placebo
(n = 480)
Age, years, mean (SD) 35.9 (7.5) 36.2 (7.3) 55.4 (5.4) 55.5 (5.3)
Race, n (%)
White 1073 (87.4) 1089 (88.0) 425 (91.0) 444 (92.5)
Black/African American 131 (10.7) 119 (9.6) 35 (7.5) 27 (5.6)
Asian 20 (1.6) 21 (1.7) 4 (0.9) 4 (0.8)
Other 3 (0.2) 9 (0.7) 3 (0.6) 5 (1.0)
Hispanic ethnicity, n (%) 117 (9.5) 111 (9.0) 28 (6.0) 23 (4.8)
Duration of HSDD, months, mean (SD) 53.9 (42.6) 57.0 (47.1) 59.5 (46.0) 61.6 (51.3)b
Weight, kg, mean (SD) 73.6 (18.0) 72.9 (17.3) 74.3 (15.4) 73.2 (15.1)b
BMI, kg/m2, mean (SD) 27.0 (6.2) 26.8 (6.5) 27.7 (5.7) 27.3 (5.4)c
BMI category (kg/m2), n (%)
Underweight (<18.5) 21 (1.7) 23 (1.9) 2 (0.4) 7 (1.5)
Normal (18.5 to <25) 559 (45.6) 569 (46.0) 164 (35.3) 175 (36.7)
Overweight (25 to <30) 330 (26.9) 341 (27.5) 165 (35.6) 161 (33.8)
Obese (‡30) 313 (25.5) 301 (24.3) 133 (28.7) 134 (28.1)
Current smoker, n (%) 159 (13.0) 157 (12.7) 53 (11.3) 55 (11.5)
Selected concomitant medications
Hormonal contraceptive use, n (%) 489 (41.1) 487 (41.0) — —
Systemic hormone therapy, n (%) — — 74 (15.9) 74 (15.4)
SSRI/SNRI use, n (%)d 47 (2.0) 21 (1.7) 12 (2.8) 12 (2.7)




























































FSFI-D score, FSDS-R13 score]) in change from baseline
body weight.
In each analysis, there was a statistically significant asso-
ciation of weight change at week 24 with baseline body
weight and treatment group such that higher baseline body
weight and treatment with flibanserin (vs. placebo) were as-
sociated with greater weight loss.
At the end of 24 weeks, 21.0% of premenopausal women
receiving flibanserin had lost ‡5% of their baseline body
weight compared with 7.8% of premenopausal women re-
ceiving placebo ( p< 0.0001); 3.8% and 2.0% of patients, re-
spectively, experienced ‡10% weight loss (Fig. 2). Similarly,
24.7% of postmenopausal women receiving flibanserin had
lost ‡5% of their baseline body weight at week 24, compared
with 7.3% of postmenopausal women receiving placebo
( p< 0.0001); 5.2% and 1.7% of patients, respectively, expe-
rienced ‡10% weight loss. At week 24, weight gain ‡7% (the
FDA definition of significant weight gain24) was observed in
1.8% and 3.4% of premenopausal women in the flibanserin
and placebo groups, respectively, and in 2.1% and 2.8% of
postmenopausal women, respectively.
To evaluate a possible dose–response effect, an analysis
of once-daily flibanserin at a dose lower than currently
recommended included 295 premenopausal women with
HSDD who received flibanserin 50mg qhs (in the VIOLET
study).9 For flibanserin 50mg qhs, LS mean weight change at
week 24 was -0.6 kg (compared with -0.1 kg for placebo and
-1.4 kg for flibanserin 100mg); weight loss of ‡5% and ‡10%
was experienced by 8.9% and 1.9% of women, respectively
(compared with 7.8% and 2.0%, respectively, for placebo and
21.0% and 3.8%, respectively, for flibanserin 100mg).
Nausea, a common adverse event with flibanserin, was
assessed as a possible contributor to weight loss. However,
the incidence of nausea in premenopausal women with HSDD
who received flibanserin 100mg in the 24-week randomized,
placebo-controlled trials was somewhat higher (7.1%) in wo-
men with weight loss <5% compared with 5.8% in women
with weight loss ‡5%. The incidence of nausea was similar in
postmenopausal women with weight loss <5% versus weight
loss ‡5% (incidence of nausea 5.3% and 5.6%, respectively).
Change in weight after longer term treatment
with flibanserin
In addition, weight loss was observed after 12 and 18
months of treatment with flibanserin (Table 4). In premeno-
pausal patients, mean (standard deviation) weight change
from parent study baseline equaled -1.0 (6.1) kg in patients
with flibanserin exposure >12 months and -1.2 (5.4) kg in
patients with flibanserin exposure >18 months. Weight loss
>5% from parent study baseline was observed in 25.4% of pa-
tients with >12 months of treatment with flibanserin and 26.9%
of patients with >18 months of treatment; weight loss ‡10%
was experienced by 7.8% and 8.4% of patients, respectively.
Discussion
In this retrospective analysis of clinical studies, flibanserin
was associated with statistically significant weight loss
compared with placebo in both premenopausal and post-
menopausal women with HSDD who received 6 months of
double-blind treatment. In addition, flibanserin-associated
weight loss was comparable in both premenopausal and
postmenopausal women. Also, there was no evidence of
weight regain based on the assessment of patients treated
with flibanserin for 18 months. Hormonal contraceptive use,
SSRI/SNRI use, BMI level, and smoking status (assessed at
baseline); nausea (assessed as an adverse event); and treat-
ment responder status (based on clinically meaningful change
in HSDD efficacy measures) did not demonstrate a significant
effect on weight change.
The patients with HSDD who participated in these clinical
trials of flibanserin were not selected for overweight or
obesity, nor did they enter the studies with the goal of losing
weight. In the patients with HSDD included in this analysis,
baseline BMI ranged from underweight to obese, with rates
of overweight (premenopausal women, 27.2%; postmeno-
pausal women, 34.4%) and obesity (premenopausal women,
24.9%; postmenopausal women, 28.2%) somewhat lower
than currently observed in the general population of adult
women in the United States,25 which may represent a healthy
user type bias in these clinical trials. Nonetheless, comparing
these findings with studies of FDA-approved weight-loss
drugs may provide some context regarding the magnitude of
weight loss observed.
In double-blind, placebo-controlled studies of FDA-approved
weight-loss drugs (i.e., lorcaserin, naltrexone/bupropion,
Table 3. Subgroup Analysis of Change
in Body Weight for Selected Baseline







Yes 49 -1.6 (0.5) 0.0861
No 2331 -0.7 (0.1)
Current smoker
Yes 159 -0.7 (0.3) 0.9405
No 1148 -0.7 (0.1)
Baseline BMI
£25 kg/m2 1157 -0.5 (0.1) 0.0015
>25 kg/m2 1263 -1.0 (0.1)
Hormonal contraceptive use
Yes 523 -0.8 (0.1) 0.4883
No 784 -0.6 (0.1)
Treatment response
SSE
Yes 471 -0.8 (0.1) 0.3303
No 812 -0.6 (0.1)
FSFI-D
Yes 495 -0.7 (0.1) 0.8016
No 810 -0.7 (0.1)
FSDS-R13
Yes 610 -0.7 (0.1) 0.9961
No 696 -0.7 (0.1)
ap Value for the contrast between the two levels of each variable,
after accounting for the effects of baseline body weight (or baseline
BMI in the model for BMI level) and treatment group.
bProtocol violation.
FSDS-R13, Female Sexual Distress Scale-Revised-desire item;
FSFI-D, Female Sexual Function Index-desire domain; LS, least
squares; SE, standard error; SSE, satisfying sexual events.























































phentermine/topiramate, and liraglutide), patients received
dietary and exercise counseling, in addition to medication.
Mean weight loss in overweight/obese patients (70%–85% of
whom were women) ranged from 5 to 10 kg for the active
study medication and 1 to 3 kg for placebo after 52 to 56
weeks of treatment.22,26–31 Studies that reported mean weight
change at interim time points showed similar weight loss at
24–28 weeks and at 52–56 weeks.26,28,31
Between 40% and 70% of patients treated with FDA-
approved weight-loss medications (and 16%–27% of patients
receiving placebo) lost ‡5% of their baseline body weight at
the typical month-12 study endpoint.22,26–31 In these studies
of women with HSDD, mean baseline BMI (premenopausal
women, 26.9 kg/m2; postmenopausal women, 27.5 kg/m2)
was substantially lower than that in studies of weight-loss
medications (35.8–38.3 kg/m2); in addition, HSDD patients
were generally not attempting to lose weight and did not
receive the ancillary therapies provided in weight-loss studies
(e.g., nutritional counseling, exercise counseling).26–31
The lower BMI in these studies, as well as the lack of
patient intent to lose weight, makes the weight loss in the
flibanserin-treated patients all the more intriguing. Mean
weight loss was 1.5–1.8 kg after 6 months of treatment with
flibanserin and 1.0 kg after 12 months of treatment, with
mean weight remaining essentially unchanged in patients
who received placebo. Weight loss ‡5% from baseline was
observed at month 6 in 21%–25% of patients receiving fli-
banserin and only 7%–8% of patients receiving placebo, and
at month 12 in 25% of flibanserin-treated patients. It is pos-
sible that weight loss observed in the flibanserin studies was
FIG. 2. Proportion of patients who
lost 5% or more, 7% or more, and 10%
or more of their baseline body weight
after 24 weeks of treatment with
flibanserin 100mg qhs or placebo
in (A) premenopausal women and
(B) postmenopausal women.
*p < 0.0001; {p < 0.05; {p < 0.01.
Table 4. Change from Baseline Body Weight









Baseline mean (SD) weight
in parent study, kg
73.2 (18.0) 73.6 (18.4)
Baseline mean (SD) weight
in open-label study, kg
73.0 (18.2) 73.3 (18.7)
Mean (SD) change from
parent study baseline
to final study visit, kg
-1.0 (6.1) -1.2 (5.4)
Mean (SD) change from
open-label study baseline
to final study visit, kg
-0.8 (5.3) -0.9 (4.4)
Percent change from parent study baseline
to final study visit, n (%)
Weight loss ‡5% 198 (25.4) 166 (26.9)
Weight loss ‡7% 133 (17.0) 111 (18.0)
Weight loss ‡10% 61 (7.8) 52 (8.4)
Weight gain ‡7% 68 (8.7) 54 (8.7)
Percent change from open-label study baseline
to final study visit, n (%)
Weight loss ‡5% 153 (19.5) 129 (20.7)
Weight loss ‡7% 91 (11.6) 80 (12.9)
Weight loss ‡10% 39 (5.0) 34 (5.5)
Weight gain ‡7% 43 (5.5) 39 (6.3)
Results at baseline and final study visit include all patients with
nonmissing data.























































limited by a floor effect, since baseline weight was lower in
these studies compared with clinical trials of weight-loss
medications.
The mechanism(s) of action by which flibanserin produces
weight loss are currently unknown. The receptor binding
affinity of flibanserin is highest for 5-HT1A receptors (as
an agonist) and 5-HT2A receptors (as an antagonist).
6 Both
5-HT1A agonist activity and 5-HT2A antagonist activity result
in the inhibition of glutamate neurons, thereby reducing
serotonin release in the prefrontal cortex.6
The complex role of serotonin in mammalian energy bal-
ance has not been completely elucidated at this time.32 Based
on evidence from numerous studies of the serotonin system, it
is generally understood that enhanced serotonergic neuro-
transmission is associated with suppression of food intake
and reduction in body weight.19,26,32 However, mirtazapine,
an atypical antidepressant with agonist effects at the 5-HT1A
receptor and antagonist effects at the 5-HT2A receptor (sim-
ilar to flibanserin), is generally known to cause weight
gain.33,34 Furthermore, flibanserin is a minor 5-HT2C receptor
antagonist,1 yet the 5-HT2C receptor agonist lorcaserin has
been approved as a weight-loss drug.22 Thus, the serotonin-
related activity of flibanserin does not appear to explain the
observed weight loss in this analysis of patients treated with
flibanserin.32
Either flibanserin affects body weight via a serotonin-
based process that is as yet unknown or weight loss associated
with flibanserin can be accounted for by non–serotonin-
related mechanisms (e.g., enhanced cortical norepinephrine
release). It is interesting to note that no significant association
was observed in this analysis for weight loss and treatment
response (defined as clinically meaningful change on HSDD
efficacy measures), suggesting that the flibanserin mecha-
nism of action for weight loss may differ from that for im-
proved sexual function.
This analysis has several limitations. The studies included
in this analysis were designed to evaluate the efficacy and
safety of flibanserin for the treatment of women with HSDD.
This analysis of change in body weight is, therefore, post hoc
and exploratory in nature. There was no systematic attempt
to collect information about the use of medications or sup-
plements known to affect body weight or participation
in programs intended to promote weight loss, nor was die-
tary or exercise counseling provided. Because this analysis
included only observed cases, weight change was not as-
sessed in patients who discontinued early from the under-
lying studies. Further investigation is needed to more
rigorously evaluate changes in body weight associated with
flibanserin treatment.
Conclusions
This retrospective analysis showed that treatment with
flibanserin 100mg qhs in women with HSDD was associated
with statistically significant weight loss compared with pla-
cebo in both premenopausal and postmenopausal patients.
Weight loss without apparent weight regain was also ob-
served during longer term, open-label flibanserin treatment of
up to 18 months. In contrast to more typical serotonergic
antidepressants, weight gain does not appear to be a clinical
concern with flibanserin. Women treated with flibanserin for
HSDD may experience weight loss.
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